Abiopharma

🔍 Arjona Ferreira Juan Camilo (Executive)

Company: Organon & Co. (OGN)

Report Date: 2026-03-31

Detailed Transactions and Holdings:

• Acquired 13,431 shares of Common Stock (Direct)
  Date: 2026-03-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 34,867.48 | transaction_form_type: 4
• Sold 4,820 shares of Common Stock at $5.7 per share (Direct)
  Date: 2026-03-31 | Code: F | equity_swap_involved: 0 | shares_owned_after: 30,047.48 | transaction_form_type: 4 | Footnotes: F1
• Acquired 200,333 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 200,333.00 | transaction_form_type: 4 | Footnotes: F2, F2, F2
• Sold 13,431 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 26,864.00 | transaction_form_type: 4 | Footnotes: F3, F4, F4

Footnotes:

• F1: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.
• F2: On March 31, 2026, the Reporting Person was granted 200,333 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.
• F3: Each RSU represents a contingent right to receive one share of Organon common stock.
• F4: On March 31, 2025, the Reporting Person was granted 40,295 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.